646 related articles for article (PubMed ID: 12828834)
1. Optimizing glycemic control with insulin glargine.
Williams JB
Diabetes Technol Ther; 2003; 5(3):471-3. PubMed ID: 12828834
[No Abstract] [Full Text] [Related]
2. An update on the long-acting insulin analogue glargine.
Thisted H; Johnsen SP; Rungby J
Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):1-11. PubMed ID: 16867163
[TBL] [Abstract][Full Text] [Related]
3. From the coalface: does glargine insulin improve hypoglycaemic episodes, glycaemic control or affect body mass in type 1 diabetic subjects who are attending a 'routine' diabetes clinic?
Distiller LA; Joffe BI
Diabetologia; 2006 Nov; 49(11):2793-4. PubMed ID: 17047914
[No Abstract] [Full Text] [Related]
4. [Flexible intensive insulin therapy: a change in mentalities].
Penfornis A; Chabroux S; Grimaldi A
Rev Med Interne; 2008 Nov; 29(11):857-60. PubMed ID: 18387717
[No Abstract] [Full Text] [Related]
5. Effects of mixing glargine and short-acting insulin analogs on glucose control.
Kaplan W; Rodriguez LM; Smith OE; Haymond MW; Heptulla RA
Diabetes Care; 2004 Nov; 27(11):2739-40. PubMed ID: 15505016
[No Abstract] [Full Text] [Related]
6. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.
Fischer JS; McLaughlin T; Loza L; Beauchamp R; Schwartz S; Kipnes M
Curr Med Res Opin; 2004 Nov; 20(11):1703-10. PubMed ID: 15537471
[TBL] [Abstract][Full Text] [Related]
7. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine.
Garg SK; Gottlieb PA; Hisatomi ME; D'Souza A; Walker AJ; Izuora KE; Chase HP
Diabetes Res Clin Pract; 2004 Oct; 66(1):49-56. PubMed ID: 15364161
[TBL] [Abstract][Full Text] [Related]
8. Effect of therapy with insulin glargine (lantus) on glycemic control in toddlers, children, and adolescents with diabetes.
Hathout EH; Fujishige L; Geach J; Ischandar M; Maruo S; Mace JW
Diabetes Technol Ther; 2003; 5(5):801-6. PubMed ID: 14633345
[TBL] [Abstract][Full Text] [Related]
9. Glycemic control with insulin glargine as part of an ethnically diverse, community-based diabetes management program.
Philis-Tsimikas A; Zhang Q; Walker C
Am J Ther; 2006; 13(6):466-72. PubMed ID: 17122525
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus.
Yki-Järvinen H
Diabetes Metab Res Rev; 2002; 18 Suppl 3():S77-81. PubMed ID: 12324990
[TBL] [Abstract][Full Text] [Related]
11. [For each diabetic the right program. Insulin therapy according to the physiology model].
Bischoff A
MMW Fortschr Med; 2003 Aug; 145(31-32):10. PubMed ID: 14524061
[No Abstract] [Full Text] [Related]
12. Comparison of insulin detemir and insulin glargine on glycemic variability in patients with type 1 and type 2 diabetes.
Tone A; Iseda I; Higuchi C; Tsukamoto K; Katayama A; Matsushita Y; Hida K; Wada J; Shikata K
Exp Clin Endocrinol Diabetes; 2010 May; 118(5):320-4. PubMed ID: 20072962
[TBL] [Abstract][Full Text] [Related]
13. Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of the long-acting insulin HOE 901 as part of a three-injection regimen.
Mohn A; Strang S; Wernicke-Panten K; Lang AM; Edge JA; Dunger DB
Diabetes Care; 2000 Apr; 23(4):557-9. PubMed ID: 10857953
[No Abstract] [Full Text] [Related]
14. [Long-acting insulin analogs: progressing slowly].
Holleman F; Hoekstra JB
Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1668-9. PubMed ID: 15453117
[TBL] [Abstract][Full Text] [Related]
15. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
[TBL] [Abstract][Full Text] [Related]
16. Insulin glargine and its place in the treatment of Types 1 and 2 diabetes mellitus.
Chatterjee S; Tringham JR; Davies MJ
Expert Opin Pharmacother; 2006 Jul; 7(10):1357-71. PubMed ID: 16805721
[TBL] [Abstract][Full Text] [Related]
17. Insulin glargine: a new basal insulin analogue.
Younis N; Soran H; Bowen-Jones D
QJM; 2002 Nov; 95(11):757-61. PubMed ID: 12391389
[No Abstract] [Full Text] [Related]
18. Will the use of insulin analogs improve glycemic control during adolescence?
Dunger DB
Pediatr Diabetes; 2003 Jun; 4(2):61-3. PubMed ID: 14655260
[No Abstract] [Full Text] [Related]
19. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients.
Yanagisawa K; Ashihara J; Obara S; Wada N; Takeuchi M; Nishino Y; Maeda S; Ishibashi Y; Yamagishi S
Diabetes Metab Res Rev; 2014 Nov; 30(8):693-700. PubMed ID: 24639403
[TBL] [Abstract][Full Text] [Related]
20. Insulin analog lispro decreases insulin resistance and improves glycemic control in an obese patient with insulin-requiring type 2 diabetes.
Darmon P; Curtillet C; Boullu S; Laugier A; Dutour A; Oliver C
Diabetes Care; 1998 Sep; 21(9):1575. PubMed ID: 9727917
[No Abstract] [Full Text] [Related]
[Next] [New Search]
